Therapeutic perspective on cardiomyopathy and heart failure in older adults through the lens of chronic inflammation
Abstract
Cardiomyopathy is a disorder of the myocardium characterized by structural and functional abnormalities that result in impaired cardiac mechanical and/or electrical function. Aging induces a natural, gradual decline in cardiac structure and function (cardiac aging) that increases susceptibility to cardiomyopathy and exacerbates pre-existing cardiomyopathy. Despite ongoing research, the complex, multifactorial nature of this process substantially increases the risk of heart failure and remains a significant clinical and scientific challenge. With rising global life expectancy, effective pharmacological strategies are urgently needed. Here, we discuss chronic inflammation as a key driver of cardiomyopathy in older adults and explore perspectives on anti-inflammatory interventions that may slow disease progression and improve outcomes for the older population.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.